Table 1 Characteristics of cancer patients treated with anti-PD-1/PD-L1 inhibitors
Patient characteristics | Patients treated with anti-PD-1/PD-L1 therapy (n = 418), n (%) |
|---|---|
Gender | Â |
Male | 298(71.3) |
Female | 120(28.7) |
Age at initiation of anti-PD-1/PD-L1 therapy (years) | Â |
Median | 64.1 |
Range | 21–87 |
Tumor type | Â |
Lung cancer | 131(31.3) |
Head and neck cancer | 57(13.6) |
Esophageal carcinoma | 51(12.2) |
Gastric carcinoma | 51(12.2) |
Urothelial carcinoma | 28(6.7) |
Colorectal cancer | 23(5.5) |
Reproductive system cancer | 19(4.5) |
Liver cancer | 17(4.1) |
Gallbladder carcinoma and bile duct carcinoma | 13(3.1) |
melanoma | 8(1.9) |
Others | 20(4.8) |
TNM clinical classification | Â |
III | 108(25.8) |
IV | 280(67.0) |
Unknown | 30(7.2) |
BMI | Â |
18.5–24.9 | 296(70.8) |
25-29.9 | 122(29.2) |
ECOG score standard | Â |
0 | 94(22.5) |
1 | 290(69.4) |
2 | 26(6.2) |
3 | 8(1.9) |
Treatment | Â |
Immunotherapy | 50(12.0) |
Immunotherapy + chemotherapy | 282(67.5) |
Immunotherapy + targeted therapy | 54(12.9) |
Immunotherapy + chemotherapy + targeted therapy | 32(7.6) |
Baseline CTC | Â |
Median | 14.8 |
Range | 1.8–86.5 |
The occurrence of irAEs | Â |
irAEs | 176(42.1) |
No-irAEs | 242(57.9) |